Articles

How do 340B contract pharmacy fees work?

The dispensing fee, a TPA fee per claim or in percent, the net benefit of one claim, and why it differs from savings measured against WAC.

A covered entity pays its contract pharmacy a dispensing fee and its TPA either a fee per claim or a percentage of the reimbursement. On a claim reimbursed $1,240, with a 340B cost of $470 and a $19.50 dispensing fee, a $12 TPA fee leaves a net benefit of $738.50; a 2 percent fee, $24.80, leaves $725.70.

Worked in full in The 340B Program Handbook by Julian R. Sterling, with every figure reproduced in a free workbook.Get the DRM-free PDF, $19.99 →

How a contract pharmacy arrangement works

Many patients of a hospital or health center fill their prescriptions at a pharmacy the entity does not own. As read in November 2026, HRSA's contract pharmacy guidelines (75 FR 10272, March 5, 2010, effective April 5, 2010) let a covered entity use multiple contract pharmacies, where the 1996 guidelines allowed a single point of pharmacy service. The entity buys the drug and keeps title to it; the wholesaler bills the entity and ships to the pharmacy, the procedure known as ship to, bill to; and the entity stays responsible for compliance, diversion and duplicate discounts included. HRSA expects the entity to hold enough information to ensure ongoing compliance and expects annual audits by an independent, outside auditor, leaving the method to the entity.

In practice the pharmacy fills the prescription from its own stock, the patient's plan pays the claim, and a third-party administrator, the TPA, reviews the claims afterwards. The TPA decides which claims meet the entity's patient definition, accumulates the eligible units by product and triggers replenishment orders at the 340B price on the entity's account. Money then flows back: the pharmacy remits what it collected on the qualified claims, less what the agreement lets it keep.

The two fees

The dispensing fee pays the pharmacy for filling the prescription on the entity's behalf. The contract pharmacy services agreement sets it: per claim, by class of drug, or as a share of the reimbursement. Neither the statute nor HRSA sets a level, and every fee on this page is a teaching assumption.

The TPA fee pays for qualifying claims, running the accumulator, ordering replenishment and reporting. A contract can set it as a fixed amount per qualified claim or as a percentage of the payer reimbursement on each claim. A percentage fee should be rounded to the cent per claim, as the contract states, so that the TPA's invoice and the entity's own recalculation agree to the cent.

The two forms differ in which claims pay for the service. A fixed fee costs the same on a cheap generic as on a specialty biologic. A percentage fee grows with the reimbursement, so it costs less than a fixed fee on low-priced claims and more on expensive ones. On a mix dominated by a few high-cost drugs, a small percentage can cost more than a fixed fee that looks high.

Net benefit of one claim

The net benefit of a contract pharmacy claim is the payer reimbursement, less the 340B acquisition cost of the units dispensed, less the dispensing fee, less the TPA fee. It is the cash the claim leaves the entity. A sample claim, not the book's case, shows both forms of TPA fee on the same claim; every amount is a teaching assumption.

LineTPA fee per claimTPA fee of 2 percent
Payer reimbursement$1,240$1,240
340B acquisition cost of the units-$470-$470
Dispensing fee to the pharmacy-$19.50-$19.50
TPA fee-$12-$24.80
Net benefit of the claim$738.50$725.70

On this claim the percentage fee costs more than the fixed one, because the reimbursement is high: 2 percent of $1,240 is $24.80. On a claim reimbursed a few dollars, the same percentage would cost cents, and the fixed fee would be the expensive one. Compare the two forms on a full year of the program's own claims, never on an average claim, because the average hides the mix.

Net benefit is not 340B savings

The same claim can be measured a second way. Savings ask what the entity avoided paying: WAC, the price of the units outside the program, less the 340B cost, less the fees per claim. With a WAC of $1,175 for the units of this claim, savings net of the dispensing fee and the fixed TPA fee are $673.50, against a net benefit of $738.50. The gap is the part of the reimbursement above WAC. It is real cash, but it comes from the payer, not from 340B, and it turns negative when a plan pays less than WAC.

Keep both figures, for different readers. Savings belong in the bridge from gross to net savings, where they can be compared with the entity's own channels (see how to calculate 340B savings). Net benefit belongs in the review of each contract pharmacy agreement, where the question is whether the arrangement pays for itself, claim by claim and pharmacy by pharmacy.

Claims that lose money

Fees are fixed per claim; the discount is not. On a low-cost generic, the gap between WAC and the 340B price can be smaller than the dispensing fee plus the TPA fee, and every qualified claim then costs the entity money. A program can leave such drugs out of its contract pharmacy arrangements, negotiate a lower fee for them, or accept the loss knowingly. What it should not do is let those claims disappear into a channel total where the profitable lines hide them. The pharmacy's own economics of the same prescription are another calculation, set out in independent pharmacy profit margin per prescription.

Restrictions change the volume behind the fees

As reported in November 2026, two federal courts of appeals, the Third and the District of Columbia Circuits, have held that the statute allows manufacturers to place some conditions on sales to contract pharmacies. State laws limiting such conditions were upheld by the Eighth Circuit in 2024 and by the Fifth Circuit in 2026, and held likely preempted by the Fourth Circuit in March and April 2026. A petition to the Supreme Court was filed on October 2, 2026; whether the Court has taken the case was not confirmed here.

For the fee review the consequence is practical. When a manufacturer limits 340B pricing to one designated pharmacy, the claims at the other pharmacies leave 340B, the gross savings on them are lost, and the fees on those claims are no longer paid. The net effect of a restriction is the lost discount less those fees. Whether a given condition is lawful, or whether a state law reaches it, is a question for the program's counsel.

What to check in the agreements and the invoices

The same fees in the book

The case is fictional: Talbryn Regional Medical Center, a 240-bed private non-profit hospital in the 340B Program as a disproportionate share hospital, with three eligible sites, an in-house retail pharmacy and four contract pharmacies served through one TPA, measured for calendar 2025. Every price, volume, fee and rate of the case is a teaching assumption, not a market figure, and the facts of your own program govern.

Talbryn works with four contract pharmacies through one TPA; three pay the TPA a fee per claim and one a percentage of the reimbursement. Across the four, the claims of 2025 bring a net benefit of $1,498,210.40 but net savings of $1,470,845.40, a difference of $27,365.00 that is payer reimbursement above WAC on the same claims. Dispensing fees total $99,594.00 and TPA fees $46,271.60. The generic tablet loses money at each of the four pharmacies, -$50,192.00 on 2,920 claims, and a single-pharmacy restriction on one biologic removes $809,600.00 of gross savings.

Mistakes that recur

Rules are described as read in November 2026 from 42 U.S.C. 256b, HRSA's contract pharmacy notices 61 FR 43549 (August 23, 1996) and 75 FR 10272 (March 5, 2010), and published reports of the court decisions on contract pharmacy conditions, and they change. No state rule is described. This page is education, not legal advice: ask the program's counsel how any rule applies to your program.

Questions people ask

What is a 340B contract pharmacy dispensing fee?

The amount the covered entity pays the pharmacy for each 340B claim it fills on the entity's behalf, set by the contract pharmacy services agreement. Neither the statute nor HRSA sets its level.

How do TPA fees work in 340B?

The TPA qualifies claims against the entity's patient definition, runs the accumulator and triggers replenishment. It charges a fixed fee per qualified claim or a percentage of the payer reimbursement, rounded to the cent per claim.

Is a percentage TPA fee better than a fee per claim?

It depends on the claim mix. A percentage fee costs less on low-priced claims and more on expensive ones. Compare the two on a full year of the program's own claims, not on an average claim.

What is the net benefit of a 340B contract pharmacy claim?

Payer reimbursement less the 340B acquisition cost, the dispensing fee and the TPA fee. It differs from savings measured against WAC by the part of the reimbursement above or below WAC.

Who is responsible for compliance at a contract pharmacy?

The covered entity. As read in November 2026, HRSA's 2010 guidelines (75 FR 10272) keep title and responsibility with the entity and expect annual independent audits of the arrangement. Ask the program's counsel how they apply.

Read the whole case

This article is one step of The 340B Program Handbook. The book follows one hospital through a full 340B year: three eligible sites and one that had to wait, the patient definition applied claim by claim, three purchase accounts and an accumulator, a carve-in and a carve-out, four contract pharmacies and their TPA, the bridge from potential to net savings, a manufacturer restriction, a rebate scenario and a self-audit that ends in a self-disclosure.

Paperback PDF edition, $19.99 Book page and free files

Free: the 340B savings calculator in Excel.

Also on this site

Case figures computed by the book's model; the hospitals and pharmacies are fictional and every price, fee and rate is a teaching assumption. Figures checked on 20 November 2026. Rules described as read on the dates given; not legal advice.